Nykredit A S Buys New Stake in DexCom, Inc. $DXCM

Nykredit A S acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, HoldingsChannel reports. The firm acquired 141,032 shares of the medical device company’s stock, valued at approximately $9,499,000.

Other institutional investors have also recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after purchasing an additional 1,515,702 shares during the period. Geode Capital Management LLC boosted its stake in DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after buying an additional 42,411 shares during the last quarter. Norges Bank purchased a new stake in DexCom in the 4th quarter valued at about $483,356,000. Invesco Ltd. grew its holdings in DexCom by 14.8% in the 4th quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after buying an additional 686,228 shares during the period. Finally, CIBC Private Wealth Group LLC increased its stake in shares of DexCom by 7.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock valued at $207,613,000 after acquiring an additional 220,313 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on DXCM shares. Mizuho boosted their price target on DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Stifel Nicolaus set a $95.00 price objective on DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings raised shares of DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $94.00 price target on shares of DexCom in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

Insider Buying and Selling at DexCom

In related news, Director Mark Foletta sold 2,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the sale, the director owned 48,852 shares in the company, valued at $4,168,052.64. This represents a 3.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the transaction, the insider owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 65,777 shares of company stock valued at $4,950,714. Insiders own 0.28% of the company’s stock.

DexCom Trading Down 2.0%

NASDAQ DXCM opened at $87.90 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The business has a 50 day moving average price of $81.24 and a 200-day moving average price of $72.35. The company has a market cap of $33.17 billion, a price-to-earnings ratio of 34.74, a P/E/G ratio of 1.47 and a beta of 1.42.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter last year, the firm posted $0.48 EPS. DexCom’s revenue was up 13.1% compared to the same quarter last year. As a group, equities analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.